These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24475827)

  • 41. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Apolipoprotein E ε2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease.
    Bonner-Jackson A; Okonkwo O; Tremont G;
    Am J Geriatr Psychiatry; 2012 Jul; 20(7):584-93. PubMed ID: 21685781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study.
    Lu PH; Thompson PM; Leow A; Lee GJ; Lee A; Yanovsky I; Parikshak N; Khoo T; Wu S; Geschwind D; Bartzokis G
    J Alzheimers Dis; 2011; 23(3):433-42. PubMed ID: 21098974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association between the ApoE polymorphisms and the MRI-defined intracranial lesions in a cohort of southern China population.
    Li Z; Yang N; Lei X; Lin C; Li N; Jiang X; Wei X; Xu B
    J Clin Lab Anal; 2019 Sep; 33(7):e22950. PubMed ID: 31199015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.
    Shaffer JL; Petrella JR; Sheldon FC; Choudhury KR; Calhoun VD; Coleman RE; Doraiswamy PM;
    Radiology; 2013 Feb; 266(2):583-91. PubMed ID: 23232293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.
    Risacher SL; Shen L; West JD; Kim S; McDonald BC; Beckett LA; Harvey DJ; Jack CR; Weiner MW; Saykin AJ;
    Neurobiol Aging; 2010 Aug; 31(8):1401-18. PubMed ID: 20620664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
    Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
    Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals.
    Ingala S; Mazzai L; Sudre CH; Salvadó G; Brugulat-Serrat A; Wottschel V; Falcon C; Operto G; Tijms B; Gispert JD; Molinuevo JL; Barkhof F;
    Neurobiol Aging; 2020 Nov; 95():104-114. PubMed ID: 32791423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
    Soares HD; Potter WZ; Pickering E; Kuhn M; Immermann FW; Shera DM; Ferm M; Dean RA; Simon AJ; Swenson F; Siuciak JA; Kaplow J; Thambisetty M; Zagouras P; Koroshetz WJ; Wan HI; Trojanowski JQ; Shaw LM;
    Arch Neurol; 2012 Oct; 69(10):1310-7. PubMed ID: 22801723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical phenotype, atrophy, and small vessel disease in
    Groot C; Sudre CH; Barkhof F; Teunissen CE; van Berckel BNM; Seo SW; Ourselin S; Scheltens P; Cardoso MJ; van der Flier WM; Ossenkoppele R
    Neurology; 2018 Nov; 91(20):e1851-e1859. PubMed ID: 30341156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.
    De Stefano N; Bartolozzi ML; Nacmias B; Zipoli V; Mortilla M; Guidi L; Siracusa G; Sorbi S; Federico A; Amato MP
    Arch Neurol; 2004 Apr; 61(4):536-40. PubMed ID: 15096402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.
    Leung KK; Bartlett JW; Barnes J; Manning EN; Ourselin S; Fox NC;
    Neurology; 2013 Feb; 80(7):648-54. PubMed ID: 23303849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.
    Hua X; Hibar DP; Ching CR; Boyle CP; Rajagopalan P; Gutman BA; Leow AD; Toga AW; Jack CR; Harvey D; Weiner MW; Thompson PM;
    Neuroimage; 2013 Feb; 66():648-61. PubMed ID: 23153970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors.
    Sluimer JD; Vrenken H; Blankenstein MA; Fox NC; Scheltens P; Barkhof F; van der Flier WM
    Neurology; 2008 May; 70(19 Pt 2):1836-41. PubMed ID: 18458218
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.
    Hua X; Leow AD; Parikshak N; Lee S; Chiang MC; Toga AW; Jack CR; Weiner MW; Thompson PM;
    Neuroimage; 2008 Nov; 43(3):458-69. PubMed ID: 18691658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease.
    Holmes C; Levy R; McLoughlin DM; Powell JF; Lovestone S
    J Neurol Neurosurg Psychiatry; 1996 Dec; 61(6):580-3. PubMed ID: 8971103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study.
    Bangen KJ; Restom K; Liu TT; Wierenga CE; Jak AJ; Salmon DP; Bondi MW
    J Alzheimers Dis; 2012; 31 Suppl 3(0):S59-74. PubMed ID: 22531427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype.
    Moffat SD; Szekely CA; Zonderman AB; Kabani NJ; Resnick SM
    Neurology; 2000 Jul; 55(1):134-6. PubMed ID: 10891924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The interaction of APOE genotype by age in amnestic mild cognitive impairment: a voxel-based morphometric study.
    Chen J; Shu H; Wang Z; Liu D; Shi Y; Zhang X; Zhang Z
    J Alzheimers Dis; 2015; 43(2):657-68. PubMed ID: 25114090
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.